Trials / Completed
CompletedNCT03263637
Study to Assess Safety, Tolerability, Pharmacokinetics and Antitumor Activity of AZD4573 in Relapsed/Refractory Haematological Malignancies
A Phase 1, Open-Label, Multicentre, Non-Randomized Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of AZD4573, a Potent and Selective CDK9 Inhibitor, in Subjects With Relapsed or Refractory Haematological Malignancies
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 44 (actual)
- Sponsor
- AstraZeneca · Industry
- Sex
- All
- Age
- 18 Years – 130 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and preliminary antitumor activity of AZD4573 in subjects with relapsed or refractory haematological malignancies.
Conditions
- Relapsed or Refractory Haematological Malignancies Including
- Acute Myeloid Leukemia
- Acute Lymphocytic Leukemia
- Chronic Lymphocytic Leukemia
- High Risk Myelodysplastic Syndrome
- Chronic Myelomonocytic Leukemia
- Richter's Syndrome
- B-cell Non-Hodgkin Lymphoma
- T-cell Non-Hodgkin Lymphoma
- Small Lymphocytic Lymphoma
- Multiple Myeloma
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | AZD4573 | AZD4573 will be administered as a intravenous (IV) infusion. |
Timeline
- Start date
- 2017-10-24
- Primary completion
- 2021-09-30
- Completion
- 2021-09-30
- First posted
- 2017-08-28
- Last updated
- 2021-10-22
Locations
12 sites across 3 countries: Germany, Netherlands, United Kingdom
Source: ClinicalTrials.gov record NCT03263637. Inclusion in this directory is not an endorsement.